3 stories mentioning TYO:4519
Every FINWIRES story that references TYO:4519, newest first.
Chugai Pharmaceutical (TYO:4519) has an average rating of overweight and mean price target of 10,240 yen, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Japanese stocks that reported recent earnings traded mixed on Monday, with gains led by companies posting solid profit growth and shareholder returns, while one major drugmaker declined despite higher quarterly earnings.Keyence (TYO:6861) shares jumped 16% after reporting full-year results, with net income attributable to owners of parent rising 12% to 445.19 billion yen as revenue increased 10% to 1.169 trillion yen. The company raised its annual dividend to 550 yen per share from 350 yen.Fanuc (TYO:6954) shares also gained 16% after posting annual results, with net income attributable to owners of parent climbing 13% to 166.54 billion yen, while revenue rose 8% to 857.83 billion yen.The company expects full-year net income attributable to owners of the parent of 184.9 billion yen and revenue of 909.6 billion yen for the financial year ending March 31, 2027. It also raised its annual dividend to 107.09 yen per share from 94.39 yen.Meanwhile, Chugai Pharmaceutical (TYO:4519) fell 16% despite reporting stronger first-quarter earnings. Net income attributable to shareholders rose 19% to 115.42 billion yen as revenue increased 12% to 321.75 billion yen. The company expects full-year revenue of 1.345 trillion yen and core net income of 485 billion yen, with an annual dividend forecast of 132 yen per share.
Chugai Pharmaceutical's (TYO:4519) net income attributable to owners rose nearly 19% to 115.4 billion yen in the first quarter from 97.2 billion yen a year earlier.The pharmaceutical group's earnings per share increased to 70.13 yen from 59.08 yen a year ago, according to a Tokyo bourse filing on Friday.Revenue grew 12% to 321.7 billion yen for the three months ended March 31 from 288.5 billion yen in the prior year.For the full year ending Dec. 31, the company expects core net income of 485 billion yen, core EPS of 295 yen, and revenue of 1.345 trillion yen.